






ITClarification of the intent of ventricular assist devices before patient
consentCourtenay R. Bruce, JD, MA,a,b Martin L. Smith, STD,c,d and Laurence B. McCullough, PhDaMoazami and Feldman1 recently proposed a single indica-
tion for mechanical circulatory support (MCS). This indica-
tion, ‘‘end-stage heart failure refractory to medical
therapy,’’1 similar to the tripartite nomenclature (‘‘destina-
tion therapy,’’ ‘‘bridge to transplant,’’ and ‘‘bridge to recov-
ery’’) by the Centers for Medicare and Medicaid Services
(CMS),2 is clinically and ethically incomplete. In this arti-
cle, we describe how the CMS tripartite nomenclature unin-
tentionally increases the risk of ethical problems
characterized by misalignments in expectations and goals
among heart failure teams, patients, and surrogates, and
thus increases the risk of an inadequate informed consent
process forMCS. Similar toMoazami and Feldman,1 we as-
sert that the current tripartite nomenclature is problematic
because of its emphasis on intended use. However, in pro-
viding only the single indication of MCS, the proposal by
Moazami and Feldman1 does not address the nature of
MCS, its short- and long-term goals, or outcomes. As a re-
sult, their proposal does not fully address the ethical prob-
lems with the CMS nomenclature.
We address this ethical challenge with an ethically
justified, clinically practical framework for describing ven-
tricular assist device (VAD) implantation. Although this
framework is particularly relevant for VADs, it is likely
equally applicable for most other types of MCS devices.
As clinical ethicists at 3 high-volume VAD programs, we
often participate in informed consent processes with VAD
candidates to elucidate patients’ and surrogates’ under-
standing and expectations of the device, trajectories, and
outcomes, and to document advance care planning prefer-
ences before device implantation. We also conduct ethics
consultations for VAD patients who already have the device
implanted, typically for the purpose of mediating conflicts
between surrogates or between surrogates and health care
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we believe that many such ethics consultations are gener-
ated unnecessarily by misalignments in expectations and
goals among heart failure clinicians, patients, and surro-
gates that originate in an exclusive focus on the intended
use of VADs and the current CMS nomenclature.
The categorization of purposes and patients within CMS
nomenclature is not hard and fast. Patients move from one
category to another as clinical factors change, a reality
acknowledged in an often-used fourth category, ‘‘bridge
to decision.’’3 Some bridge to transplant patients who do
not perform as well as expected or intended on a device
do not receive a heart transplant (eg, a patient who suffers
from a disabling stroke). They then shift to the category
of ‘‘destination therapy.’’3 Approximately 17% of destina-
tion therapy patients receive a transplant after correcting
psychosocial or medical contraindications to transplanta-
tion, for example, kidney dysfunction or a lack of support-
ive networks.4 We refer to this shift from one intended use
of a device (eg, bridge to transplant) to another (eg, destina-
tion therapy), as risk of drift.
There are 2 significant components of the informed con-
sent process that need special attention for that process to
be adequate: transparent disclosure and patient comprehen-
sion and understanding.5 These components of the informed
consent process are undermined by reliance on the CMS no-
menclature because it masks the risk of drift. For instance,
the phrase ‘‘destination therapy’’ masks the reality that there
are at least 4 possible destinations, as follows: (1) permanent
implantation with disease-related and iatrogenic morbidity
but with an acceptable quality of life; (2) permanent implan-
tation and prolonged intensive care unit admission, with
disease-related and iatrogenic morbidity and loss of func-
tional status resulting in an unacceptable quality of life;
(3) permanent implantation followed by explantation and
transplantation, with disease-related and iatrogenic morbid-
ity and an acceptable quality of life; and (4) permanent
implantation followed by explantation, transplantation,
and prolonged intensive care unit admission, resulting in
disease-related and iatrogenic morbidity and loss of func-
tional status resulting in an unacceptable quality of life.
Essential to adequate patient comprehension and evalua-
tion of such outcomes is that patients can reason from pres-
ent events to future consequences and have a sense of the
probability that disclosed potential consequences may in-
deed occur.5 Unfortunately, the CMS categories invite un-
wary clinicians to focus almost exclusively on the use ordiovascular Surgery c Volume 145, Number 6 1423







Lintended purposes of the device. As a result, patients are put
at increased risk of failing to grasp the nature and likelihood
of future consequences attendant upon each of the therapeu-
tic options available or the possible outcomes that may be
experienced. The options experienced by or available to
patients are unjustifiably limited.
Although the nature, purpose, and possible outcomes of
an intervention are distinct concepts and requisites for
informed consent, within the CMS nomenclature these dis-
tinct concepts are fused and therefore can create confusion,
which increases the risk of unintentional but real and potent
preventable ethical conflict. Consider the following pre-
ventable ethical problems characterized by misalignments
in expectations and goals among clinicians, patients, and
surrogates.
First, because of the tripartite nomenclature, patients may
not grasp the nature and likelihood of possible trajectories
and outcomes that they may experience. As a result, they
may not be able to account for why some patients receive
transplants and others do not.4 Second, of greater concern
with the nomenclature and its focus on intended purposes
is the likelihood that patients and surrogates are not pre-
pared for outcomes deviating from the originally intended
purpose of the device. Consider a case involving a patient
who initially is considered a bridge to transplant candidate
for whom a series of complications develop after VAD im-
plantation, perhaps a stroke or renal, hepatic, and respira-
tory failure.3 The surrogate may resist discussions about
medical futility and forgoing life-sustaining therapies, cit-
ing pre-intervention discussions focused on transplantation
and the term ‘‘bridge to transplant.’’
Third, reliance on CMS nomenclature and intended pur-
poses may preclude conducting advance care planning.
Some VAD programs integrate palliative medicine consul-
tations for patients receiving VADs as destination therapy,
for the purpose of elucidating quality-of-life preferences
before device implantation.6,7 However, if only
destination therapy patients receive such consultations
before implantation, patients for whom the intended
purpose of the device shifts may not receive such referrals
or, alternatively, receive them too late for palliative
medicine to be fully helpful.
In recognition of the unintentional but preventable ethical
problems resulting from the CMS nomenclature, we call for
abandoning it and propose an alternative framework.
Although a few points mentioned within the framework
have been advanced by other investigators, for example,
the value of proactive advance care planning,7,8 we
believe this framework is unique in that it is a step-wise
approach that defines the nature, purpose, short- and long-
term goals of VAD implantation, and responsible manage-
ment of outcomes, thereby distinguishing specific, essential
elements of informed consent that currently are fused
within the CMS nomenclature. The framework also1424 The Journal of Thoracic and Cardiovascular Surprovides some of the necessary components for shared de-
cision making between the patient and clinician.8,9STEP 1: USE A NEW DESCRIPTION OF THE
NATURE AND PURPOSE OF VAD
When addressing the nature and purpose of a VAD in the
informed consent process, the following description should
be used: VAD implantation is a surgical introduction of
a life-sustaining intervention (nature) that is designed to
prolong life with the goal of an acceptable outcome from
continued clinical care (purpose), secondary to (as Moa-
zami and Feldman1 have proposed) end-stage heart failure
refractory to medical therapy.STEP 2: DESCRIBE SHORT- AND LONG-TERM
GOALS
The use of a life-sustaining treatment, such as a VAD, is
justified as long as both its short-term goal (prolonging life)
and long-term goal (preserving for the patient some interac-
tive capacity and an acceptable quality of life) are being
achieved.10 Patients need to understand the centrality of
clinical judgments about resulting functional status and pa-
tients’ own judgments about acceptable quality of life.
Patients need to understand that VAD placement as an ongo-
ing life-sustaining treatment frequently does not lead to
device removal because the heart may not recover and trans-
plantation may not be possible. Clinicians should caution
that the probability of transplant may evolve over time
(because of risk of drift), which may necessitate multidisci-
plinary reviews concerning candidacy for transplantation.STEP 3: NEGOTIATE STOPPING RULES TO
MANAGE OUTCOMES
The objective of initial conversations about stopping
rules is to assist patients, in advance of the need for them,
to deliberate about the quality of life associated with out-
comes. Clinicians should discuss with patients the possible
scenarios that can affect quality of life adversely such as
debilitative comorbid conditions and VAD-associated com-
plications.6More detailed conversations can take place after
VAD placement if there is a negative shift in a patient’s per-
formance status. Patients should be encouraged to make
advance decisions as explicit as possible and communicate
those decisions to their surrogate decision makers.
We believe that abandoning the current CMS tripartite
nomenclature in favor of a new, more informative frame-
work will help mitigate or prevent the ethical problems
we identified.References
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